America and Britain Finalize Tariff-Free Agreement on Pharmaceuticals.
The UK and US have hammered out a major bilateral deal that will keep no import taxes on British pharmaceutical products being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to boost expenditure on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these vital products will stay at zero for a timeframe of three years.
This deal is in response to recent threats to significantly raise import taxes on branded pharmaceutical products, with figures mentioned up to 100%.
"This arrangement with the UK reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to U.S.–U.K. drug exports," an announcement noted.
Commercial Significance
Pharmaceuticals constitute one of the UK's most significant export categories to the United States, which is easily the biggest buyer for leading UK drugmakers.
Trade data reveal that in the year prior to last September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that span.
"This deal safeguards work, increases capital expenditure and paves the way for the UK to emerge as a worldwide center for life sciences," a minister commented.
Detailed NHS Changes
The agreement includes several notable changes from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to raise overall public funding on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments exceeded twenty percent.
Industry Background
The pact takes place against a protracted row between the sector and the British authorities over spending levels and regulatory access.
These tensions were exacerbated by claims that American patients were paying a premium for the same drugs than people in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or abandoned, while major investments have been announced toward projects in the United States.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a share of its total funding over the previous ten-year period.
